Allen S. Lichter

Biochemistry, Genetics and Molecular Biology · Life Sciences

62h-index14.4kcitations208works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(51), Advanced Radiotherapy Techniques(50), Lung Cancer Diagnosis and Treatment(17), Medical Imaging Techniques and Applications(17), Economic and Financial Impacts of Cancer(17)

Publications204 total

Conversations with the Pioneers of Oncology: Dr. Allen Lichter
2024
Conversations with the Pioneers of Oncology: Dr. Allen Lichter
2024
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy
Annals of Oncology·2023· 11 citedOpen Access
US Government Payer–Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
Journal of Clinical Oncology·2023· 18 cited
The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
Blood Advances·2022· 10 citedOpen Access
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
Journal of Clinical Oncology·2021· 41 cited
The Treatment of Breast Cancer with Excision Followed by Radiation Therapy
Breast Cancer·2021
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
Journal of Clinical Oncology·2021· 49 citedOpen Access
Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation
JAMA Oncology·2020· 25 cited
Oncology’s “Hockey Stick” Moment for the Cost of Cancer Drugs—The Climate Is About to Change
JAMA Oncology·2020· 15 cited
Interventional Pharmacoeconomics
The Cancer Journal·2020· 16 cited
Introduction by the Guest Editors
The Cancer Journal·2020
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
Clinical Pharmacology & Therapeutics·2020· 50 cited
Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment
JAMA Oncology·2019· 53 cited
Potential for value-based prescribing of oral oncology drugs
Annals of Oncology·2018· 6 citedOpen Access
Transforming the future of health together: The <scp><i>Learning Health Systems Consensus Action Plan</i></scp>
Learning Health Systems·2018· 26 citedOpen Access
From Choosing Wisely to Using Wisely: Increasing the Value of Cancer Care Through Clinical Research
Journal of Clinical Oncology·2018· 9 citedOpen Access
The value in cancer care consortium: addressing financial toxicity.
PubMed·2017
Conflict of Interest and the Integrity of the Medical Profession
JAMA·2017· 26 cited
Oncology and Health Care Policy
Elsevier eBooks·2014
page 1 of 11Next →

Frequent Co-authors

Randall K. Ten Haken(13), Mary K. Martel(11), Benedick A. Fraass(11), Eli Glatstein(8), Howard M. Sandler(8), Andrew T. Turrisi(6), Daniel L. McShan(6), David N. Danforth(5), Teresa D'Angelo(5), Lon H. Marsh(5), Mark B. Hazuka(5), Seth M. Steinberg(4), Marc E. Lippman(4), Theodore S. Lawrence(4), Marc L. Kessler(4), Lori J. Pierce(3), Robert Makuch(3), Mary J. Matthews(3), John D. Minna(3), Daniel C. Ihde(3)